Michael Kauffman, MD and CEO from Karyopharm Therapeutics Inc discusses developments of Phase 3 trial: BOSTON – Bortezomib in combination with Selinexor for treating myeloma at the 2017 American Society of Hematology.
Developments of Phase 3 Trial: BOSTON Bortezomib in combination with Selinexor for treating Myeloma
